Prostatype Genomics AB (OSTO:PROGEN) Days Inventory : 0.00 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Prostatype Genomics AB's Average Total Inventories for the three months ended in Jun. 2023 was kr0.16 Mil. Prostatype Genomics AB's Cost of Goods Sold for the three months ended in Jun. 2023 was kr0.00 Mil.

The historical rank and industry rank for Prostatype Genomics AB's Days Inventory or its related term are showing as below:

OSTO:PROGEN's Days Inventory is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 69.24
* Ranked among companies with meaningful Days Inventory only.

Prostatype Genomics AB's Days Inventory stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year. Prostatype Genomics AB's Inventory Turnover for the three months ended in Jun. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Prostatype Genomics AB's Inventory-to-Revenue for the three months ended in Jun. 2023 was 2.79.

Prostatype Genomics AB Days Inventory Historical Data

The historical data trend for Prostatype Genomics AB's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Days Inventory Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Days Inventory

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Days Inventory	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Prostatype Genomics AB's Days Inventory

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's Days Inventory Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Days Inventory distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Days Inventory falls into.

Prostatype Genomics AB Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Prostatype Genomics AB's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.044	+	0.203)	/	2 )	/	-2.372	*	365
=	0.1235					/	-2.372	*	365
=	N/A

Prostatype Genomics AB's Days Inventory for the quarter that ended in Jun. 2023 is calculated as:

	Days Inventory (Q: Jun. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Mar. 2023 )	+	Total Inventories (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (0.158	+	0.155)	/	2 )	/	0	*	365 / 4
=	0.1565					/	0	*	365 / 4
=	N/A

Prostatype Genomics AB (OSTO:PROGEN) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Prostatype Genomics AB's Inventory Turnover for the three months ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0.1565
	=	0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Prostatype Genomics AB's Inventory to Revenue for the three months ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.1565	/	0.056
	=	2.79

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Prostatype Genomics AB Days Inventory Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines